This article is more than 5 years old. Information may no longer be current.
Two biomarkers predicted higher risk for HF
Velagaleti R. Circulation. 2010;122:1700-1706.
Click Here to Manage Email Alerts
Researchers from Boston University have identified a biomarker panel that predicted risk for HF in those without prevalent coronary heart disease.
The panel was tested in 2,754 participants from the Framingham Heart Study. Of these participants, 118 had a history of MI or unstable angina. Approximately half of the participants had a baseline Framingham risk score-predicted 10-year CHD risk of at least 10%.
The participants provided biosamples that were then analyzed for the presence of six biomarkers: aldosterone-to-renin ratio, CRP, plasminogen activator inhibitor-1, B-type natriuretic peptide, homocysteine and the urinary albumin-to-creatinine ratio.
After a mean follow-up of 9.4 years, 95 participants developed HF. On multivariate analysis, the panel of biomarkers was significantly related to the risk for HF. On backward elimination, the B-type natriuretic peptide and the urinary albumin-to-creatinine ratio were key biomarkers of HF risk. For B-type natriuretic peptide, the risk for HF was increased by 52%. For urinary albumin-to-creatinine ratio, the risk for HF was increased by 35%. When present together, the HF risk increased 10-fold.
“Although the exact mechanisms underlying the predictive value of B-type natriuretic peptide and urinary albumin-to-creatinine cannot be conclusively determined from epidemiological data alone, the results from our investigation, if confirmed, can potentially be used in clinical settings to evaluate HF risk and to identify specific high-risk individuals,” the researchers wrote.
 |
Follow CardiologyToday.com on Twitter. |